Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

MANHATTAN — The Big 12 announced a hefty fine against Kansas State football for not accepting a bowl bid following the 2025 season. The Big 12 announced it would fine Kansas State and Iowa State ...

Ohio State changed the tide of The Game and beat Michigan 27-9 to snap a four-game losing streak in the rivalry. With the return of wide receivers Carnell Tate and Jeremiah Smith from injury, Ohio ...

Replimune Group announced that the U.S. Food and Drug Administration has accepted the resubmission of its Biologics License Application for RP1 in combination with nivolumab, targeting advanced ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

We recently published 10 Stocks Losing Big Amid Market Boom. Replimune Group, Inc. (NASDAQ:REPL) is one of the worst performers on Thursday. Replimune extended losses to a second consecutive day on ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

U.S. Rep. Chip Roy, R-Texas, announced Thursday that he is running to become the next Texas Attorney General. Roy, who represents Texas' 21st Congressional District in the U.S. House, made the ...

Shares of Replimune (NASDAQ:REPL) plunged ~38% in the premarket on Monday after Stat News reported that the FDA’s top regulator of cancer drugs intervened during the review of the company’s lead asset ...

Investing.com -- Replimune Group Inc (NASDAQ: REPL) stock tumbled 36% premarket after STAT reported that the FDA’s top cancer drug regulator intervened late in the review process of the company’s skin ...